[Financial Performance Overview](index=1&type=section&id=Financial%20Performance%20Overview) This section provides an overview of the company's financial performance, including management's strategic insights, detailed GAAP and non-GAAP results for fiscal year 2024, and future business outlook [Management Commentary](index=1&type=section&id=Management%20Commentary) Management highlights over $210 million in annualized client financial impact and focuses on targeted innovation for fiscal 2025, including new denial prevention functionality - The company's solutions are delivering an annualized financial impact of more than **$210 million** to its clients[2](index=2&type=chunk) - Fiscal 2025 will focus on targeted innovation, highlighted by the new denial prevention functionality within the eValuator solution, designed to help clients prevent denials in real-time[2](index=2&type=chunk) [Fiscal Fourth Quarter and Full Year 2024 GAAP Financial Results](index=1&type=section&id=Fiscal%20Fourth%20Quarter%20and%20Full%20Year%202024%20GAAP%20Financial%20Results) Fiscal 2024 GAAP results show total revenue decreased to $17.9 million, while net loss significantly improved to ($10.2 million) due to the absence of prior year impairment charges Fiscal Year Revenue Performance (GAAP) | Category | Fiscal Year 2024 | Fiscal Year 2023 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $17.9 million | $22.6 million | -20.8% | | SaaS Revenue | $11.8 million | $14.1 million | -16.3% | Quarterly Revenue Performance (GAAP) | Category | Q4 2024 | Q4 2023 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $4.7 million | $5.4 million | -13.0% | | SaaS Revenue | $3.1 million | $3.4 million | -8.8% | Net Loss Performance (GAAP) | Period | Net Loss 2024 | Net Loss 2023 | | :--- | :--- | :--- | | Fiscal Year | ($10.2 million) | ($18.7 million) | | Fourth Quarter | ($2.1 million) | ($1.4 million) | - The improvement in the full-year net loss was primarily the result of **$10.8 million** of non-cash impairment charges incurred in fiscal 2023 that did not recur in fiscal 2024[5](index=5&type=chunk) - As of January 31, 2025, cash and cash equivalents were **$2.2 million**, down from **$3.2 million** a year prior. The outstanding balance on the revolving credit facility was reduced to **$1.0 million** from **$1.5 million**[6](index=6&type=chunk) [Fiscal Fourth Quarter and Full Year 2024 Non-GAAP Financial Results](index=2&type=section&id=Fiscal%20Fourth%20Quarter%20and%20Full%20Year%202024%20Non-GAAP%20Financial%20Results) Fiscal 2024 Non-GAAP results show Adjusted EBITDA improved to a ($1.3 million) loss, while Booked SaaS ACV decreased to $14.0 million but is projected to recover Adjusted EBITDA Performance (Non-GAAP) | Period | Adjusted EBITDA 2024 | Adjusted EBITDA 2023 | | :--- | :--- | :--- | | Fiscal Year | ($1.3 million) | ($1.4 million) | | Fourth Quarter | $35,000 | $0.4 million | Booked SaaS Annual Contract Value (ACV) | Date | Total Booked SaaS ACV | Implemented ACV | Unimplemented ACV | | :--- | :--- | :--- | :--- | | Jan 31, 2024 | $15.0 million | N/A | N/A | | Jan 31, 2025 | $14.0 million | $12.3 million | $1.7 million | | Apr 30, 2025 (Expected) | $14.6 million | $13.1 million | $1.5 million | - The decrease in booked SaaS ACV was largely due to previously reported client non-renewals, which was partially offset by **$3.5 million** of new bookings during fiscal year 2025[8](index=8&type=chunk) [Business Outlook](index=2&type=section&id=Business%20Outlook) The company expects to achieve a positive Adjusted EBITDA run rate in the first half of fiscal 2025 but refrains from specific bookings guidance due to timing unpredictability - The company reiterated its expectation to achieve an adjusted EBITDA positive run rate during the first half of fiscal 2025[10](index=10&type=chunk) - Due to continued unpredictability in the timing of closing new contracts, the Company has not provided more specific guidance related to the timing of bookings[10](index=10&type=chunk) [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) This section presents the company's consolidated financial statements, including detailed statements of operations, balance sheets, and cash flows for the reported periods [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Fiscal year 2024 statements of operations show total revenues decreased to $17.9 million, while operating expenses significantly declined, leading to a reduced net loss of ($10.2 million) Fiscal Year 2024 vs 2023 Statement of Operations Highlights | Metric | Fiscal Year 2024 | Fiscal Year 2023 | | :--- | :--- | :--- | | Total Revenues | $17,901,000 | $22,596,000 | | Total Operating Expenses | $25,930,000 | $42,243,000 | | Impairment Charges | $0 | $10,776,000 | | Operating Loss | ($8,029,000) | ($19,647,000) | | Net Loss | ($10,159,000) | ($18,697,000) | | Basic and Diluted EPS | ($2.53) | ($4.96) | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) As of January 31, 2025, total assets decreased to $35.6 million, primarily due to lower cash and receivables, resulting in a decline in total stockholders' equity to $12.3 million Balance Sheet Highlights (As of Jan 31) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $2,183,000 | $3,190,000 | | Total Current Assets | $5,777,000 | $8,836,000 | | Total Assets | $35,579,000 | $41,735,000 | | Total Current Liabilities | $23,062,000 | $13,682,000 | | Total Liabilities | $23,302,000 | $22,921,000 | | Total Stockholders' Equity | $12,277,000 | $18,814,000 | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Fiscal year 2024 cash flow statements show improved net cash used in operating activities at ($1.5 million), with a net decrease in cash and cash equivalents of ($1.0 million) for the period Cash Flow Summary (Fiscal Year) | Cash Flow Activity | 2024 | 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | ($1,514,000) | ($2,215,000) | | Net cash used in investing activities | ($858,000) | ($1,621,000) | | Net cash provided by financing activities | $1,365,000 | $428,000 | | **Net decrease in cash** | **($1,007,000)** | **($3,408,000)** | | Cash at end of period | $2,183,000 | $3,190,000 | [Supplemental Information](index=2&type=section&id=Supplemental%20Information) This section provides supplemental financial data, including the reconciliation of GAAP net loss to non-GAAP Adjusted EBITDA, and details for the upcoming conference call [Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA](index=8&type=section&id=Reconciliation%20of%20Net%20Loss%20to%20Non-GAAP%20Adjusted%20EBITDA) This section reconciles the GAAP net loss to non-GAAP Adjusted EBITDA, showing an Adjusted EBITDA loss of ($1.3 million) for fiscal year 2024 after various adjustments Reconciliation of Net Loss to Adjusted EBITDA (Fiscal Year) | (in thousands) | 2024 | 2023 | | :--- | :--- | :--- | | Net loss | $(10,159) | $(18,697) | | Plus: Interest, Taxes, D&A | $6,357 | $5,254 | | Plus: Share-based compensation | $1,964 | $2,102 | | Plus: Impairment charges | $0 | $10,776 | | Other adjustments | $542 | $(821) | | **Adjusted EBITDA** | **$(1,296)** | **$(1,386)** | - Adjusted EBITDA is a non-GAAP measure defined as net earnings (loss) adjusted for interest, taxes, depreciation, amortization, share-based compensation, and other significant non-recurring or transactional expenses[15](index=15&type=chunk) [Conference Call Information](index=2&type=section&id=Conference%20Call%20Information) Details for the upcoming conference call on May 2, 2025, at 9:00 AM ET are provided, including access methods and replay availability - A conference call will be held on Friday, May 2, 2025, at **9:00 AM ET**[11](index=11&type=chunk) - A replay of the call will be available by phone until May 9, 2025, and an online replay will be available for six months in the Investor Relations section of the company's website[12](index=12&type=chunk)

Core Viewpoint - Streamline Health Solutions, Inc. reported a decline in revenue for the fourth quarter and fiscal year 2024, primarily due to SaaS non-renewals and lower revenue from legacy contracts, while emphasizing a focus on innovation and client engagement to drive future growth [1][3][4]. Financial Performance - Total revenue for Q4 2024 was $4.7 million, down from $5.4 million in Q4 2023. For the fiscal year, revenue totaled $17.9 million compared to $22.6 million in the previous year [3]. - SaaS revenue for Q4 2024 was $3.1 million, representing 66% of total revenue, compared to $3.4 million (64%) in Q4 2023. For the fiscal year, SaaS revenue was $11.8 million (66%) versus $14.1 million (62%) in fiscal 2023 [4]. - The net loss for Q4 2024 was ($2.1 million), compared to a net loss of ($1.4 million) in Q4 2023. The total net loss for fiscal 2024 was ($10.2 million), an improvement from ($18.7 million) in fiscal 2023 [5]. Cash Position and Liabilities - Cash and cash equivalents as of January 31, 2025, were $2.2 million, down from $3.2 million a year earlier. The company had an outstanding balance of $1.0 million on its revolving credit facility [6]. - Total liabilities increased to $23.3 million as of January 31, 2025, compared to $22.9 million in the previous year [23]. Adjusted EBITDA - Adjusted EBITDA for Q4 2024 was $35,000, down from $0.4 million in Q4 2023. For the fiscal year, adjusted EBITDA was a loss of ($1.3 million), slightly improved from a loss of ($1.4 million) in fiscal 2023 [7][28]. Booked SaaS Annual Contract Value (ACV) - As of January 31, 2025, the total Booked SaaS ACV was $14.0 million, down from $15.0 million a year earlier, largely due to client non-renewals, but offset by $3.5 million in new bookings during fiscal 2025 [8][9]. Future Outlook - The company expects to achieve an adjusted EBITDA positive run rate during the first half of fiscal 2025, although specific guidance on timing for bookings has not been provided due to unpredictability [11].

Core Insights - Streamline Health Solutions, Inc. has signed a contract with an 1,100 bed health system in Ohio to utilize its eValuator pre-bill code audit technology, aimed at improving coding accuracy and financial performance [1][2]. Company Overview - Streamline Health is at the forefront of enhancing financial performance in healthcare systems through pre-bill technology solutions, specifically with its AI-enhanced eValuator tool that helps providers accurately capture and bill for care, minimizing denials [2][3]. - The CEO of Streamline Health expressed commitment to supporting the health system's revenue cycle, emphasizing the potential for significant financial impact and allowing clients to focus on community care [3]. Industry Context - The adoption of eValuator technology reflects a broader industry movement towards improving financial performance in healthcare, addressing revenue leakage, and ensuring compliance in billing practices [2][3].

Core Insights - Streamline Health Solutions has signed a contract to implement its RevID automated charge reconciliation technology with a 120-bed health system in Kentucky, marking its fourth CommunityWorks Oracle EHR client [1][2][3] - The RevID solution aims to enhance hospital financial performance by capturing 100% of earned revenue and accelerating cash flow through improved charge capture processes [2][3] Company Overview - Streamline Health Solutions focuses on providing integrated solutions and technology-enabled services to help healthcare organizations address revenue leakage and improve financial performance [3] - The partnership with Oracle Health is expected to strengthen Streamline Health's ability to deliver pre-bill solutions that integrate seamlessly with leading EHR platforms [3]

Core Insights - Streamline Health Solutions, Inc. has signed a contract with Deaconess Health System to utilize its eValuator solution for enhancing pre-bill coding accuracy and financial outcomes [1][3][4] - The eValuator solution is designed to improve coding and billing workflows, particularly within the mid-revenue cycle, leveraging automation to enhance accuracy [2][3] - Streamline Health aims to lead an industry movement focused on improving financial performance for health systems through advanced pre-bill technology solutions [3][4] Company Overview - Streamline Health Solutions, Inc. (NASDAQ:STRM) provides integrated solutions and technology-enabled services to help healthcare organizations address revenue leakage and enhance financial performance [5] - The company’s offerings include analytics that drive compliant revenue, contributing to improved financial outcomes across healthcare enterprises [5] Partner Overview - Deaconess Health System serves over 1.5 million residents across southwestern Indiana, western Kentucky, and southeastern Illinois, operating 19 hospital locations [5]

Core Insights - Streamline Health Solutions, Inc. has signed a new contract for the use of its RevID technology with a 400-bed health system in Western Texas, in partnership with Oracle Health [1] - RevID's automated charge reconciliation aims to capture 100% of earned revenue for hospitals, eliminating charge capture gaps and accelerating cash flow [2] - The integration of RevID with Oracle Health's Soarian billing platform enhances financial operations for health systems by automating charge reconciliation processes [2] Company Overview - Streamline Health Solutions focuses on enabling healthcare organizations to address revenue leakage and improve financial performance through integrated solutions and analytics [3] - The company is expanding its presence in Texas, a market identified as ideal for growth due to its innovative healthcare providers [3]

Financial Data and Key Metrics Changes - Total revenue for Q3 2024 was $4.4 million, down from $6.1 million in Q3 2023, with a nine-month total of $13.2 million compared to $17.2 million in the same period last year [37] - SaaS revenue for Q3 2024 was $2.9 million, representing 66% of total revenue, compared to $3.9 million (64%) in Q3 2023, with a nine-month total of $8.7 million (66%) versus $10.6 million (62%) in the prior year [38] - Net loss for Q3 2024 was $2.5 million, significantly improved from a net loss of $11.9 million in Q3 2023, with a nine-month loss of $8 million compared to $17.3 million in the previous year [39] - Adjusted EBITDA for Q3 2024 was a loss of $0.3 million, compared to a gain of $0.4 million in Q3 2023, reflecting lower total revenue and higher interest expenses [40] Business Line Data and Key Metrics Changes - Booked SaaS ACV as of October 31, 2024, totaled $14.1 million, with $12 million already implemented, indicating a strong pipeline for future revenue growth [36] - The company successfully closed new contracts with an aggregate SaaS ACV of $700,000 during Q3 2024, including the launch of the new eValuator quality module [12][13] Market Data and Key Metrics Changes - The healthcare revenue cycle departments are facing challenges due to complex reimbursement systems and labor market issues, which Streamline Health Solutions aims to address through its automation and insights [15][16] - The company is focusing on enhancing its solutions to provide actionable insights that help health systems improve their revenue cycle management [17][18] Company Strategy and Development Direction - Streamline Health Solutions is prioritizing the development of its eValuator and RevID platforms, with a focus on automation and quality measurement as key strategic initiatives [20][21] - The company is exploring additional non-equity capital sources to accelerate growth plans and enhance its product offerings [43] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving an adjusted EBITDA positive run rate in the first half of fiscal 2025, earlier than previously expected, due to strong client interest and successful contract implementations [13][36] - The company anticipates significant revenue growth in fiscal 2025, driven by new bookings and the expansion of existing client relationships [43] Other Important Information - The new quality module for eValuator was developed through a nine-month pilot program and has already seen rapid adoption among clients, indicating strong market demand [19][22] - The company has made significant progress in developing best practice manuals for clients to enhance the implementation of its solutions [25] Q&A Session Summary Question: Can you expand on the 835 analysis and its implications for clients? - Management explained that incorporating 835 data allows for preemptive addressing of payer behaviors, enhancing the accuracy of billing and reimbursement processes [46][48] Question: How does the ROI for eValuator change with this implementation? - The response highlighted that the new approach allows leaders to compare cash impacts directly, potentially driving higher ROI by focusing on higher reimbursement rates [49][50] Question: What gives confidence to bring breakeven guidance forward? - Management noted strong client success stories and significant interest generated from recent marketing efforts, which are expected to translate into new contracts [52][55]

Core Insights - Streamline Health Solutions, Inc. reported a net loss of $2.5 million in Q3 fiscal 2024, a significant improvement from a net loss of $11.9 million in Q3 fiscal 2023 [1][5] - The company reiterated its expectation for a $15.5 million implemented SaaS ARR adjusted EBITDA breakeven run rate and has accelerated this expectation to the first half of fiscal 2025 [1][10] Financial Performance - Total revenue for Q3 fiscal 2024 was $4.4 million, down from $6.1 million in Q3 fiscal 2023. For the nine months ended October 31, 2024, revenue totaled $13.2 million compared to $17.2 million in the same period of fiscal 2023 [3][21] - SaaS revenue for Q3 fiscal 2024 was $2.9 million, representing 66% of total revenue, compared to $3.9 million (64% of total revenue) in Q3 fiscal 2023. For the nine months ended October 31, 2024, SaaS revenue was $8.7 million (66% of total revenue) compared to $10.6 million (62% of total revenue) in the same period of fiscal 2023 [4][21] Cost Management - The net loss for the nine months ended October 31, 2024, was $8.0 million, down from $17.3 million in the same period of fiscal 2023. This improvement was attributed to lower total revenues and higher interest expenses, offset by reductions in cost of sales, SG&A, and R&D expenses totaling $1.9 million and $5.3 million, respectively [5][7] - Adjusted EBITDA for Q3 fiscal 2024 was a loss of $0.3 million, compared to a gain of $0.4 million in Q3 fiscal 2023. For the nine months ended October 31, 2024, adjusted EBITDA was a loss of $1.3 million, an improvement from a loss of $1.8 million in the same period of fiscal 2023 [7][10] Cash Position - As of October 31, 2024, cash and cash equivalents were $0.8 million, down from $3.2 million as of January 31, 2024. The company had no outstanding balance on its revolving credit facility as of October 31, 2024, compared to $1.5 million as of January 31, 2024 [6][21] - The company received a $1.0 million draw from its revolving line of credit on November 20, 2024 [6] Strategic Outlook - The company’s total Booked SaaS Annual Contract Value (ACV) was $14.1 million as of October 31, 2024, down from $15.0 million as of January 31, 2024. However, $12.0 million of the Booked SaaS ACV was implemented as of October 31, 2024, compared to $11.1 million as of January 31, 2024 [8][10] - Management expressed optimism about expanding client relationships and improving financial performance, leading to an accelerated timeline for achieving adjusted EBITDA breakeven [11]

Company Overview - Streamline Health Solutions, Inc. (NASDAQ: STRM) is a leading provider of solutions aimed at improving financial performance for healthcare providers [3] - The company focuses on integrated solutions, technology-enabled services, and analytics to address revenue leakage and enhance financial performance across healthcare organizations [3] Recent Developments - Streamline Health has expanded its relationship with an existing eValuator client by including the newly released eValuator Quality Module [1] - The company anticipates a 25% increase in SaaS revenues from this eValuator relationship due to the new module [1] Industry Impact - Streamline Health is at the forefront of an industry movement to enhance hospital financial performance through pre-bill technology solutions [2] - The eValuator's AI-powered pre-bill code auditing analyzes 100% of encounters in real-time, ensuring accurate billing and payment for healthcare providers while minimizing denials [2] - The eValuator Quality Module allows health systems to assess the risk score of individual claims and their impact on overall quality measurement in real-time, replacing manual risk scoring practices [2]

Core Viewpoint - Streamline Health Solutions, Inc. will implement a 1-for-15 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective October 4, 2024 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will combine every 15 shares of Common Stock into one share, with no fractional shares issued; instead, cash will be paid for any fractional shares [2]. - The new CUSIP number for the Common Stock post-split will be 86323X205, and it will continue trading under the symbol "STRM" on The Nasdaq Capital Market [2]. - The reverse stock split will also apply to outstanding securities convertible into Common Stock, with all related agreements and equity awards adjusted proportionately [3]. Group 2: Administrative Aspects - Computershare Inc. will act as the exchange agent for the reverse stock split, and stockholders holding shares electronically will not need to take action to receive post-split shares [4]. - Stockholders owning shares through banks or brokers will have their positions adjusted automatically and will receive cash for any fractional shares according to their respective institutions' processes [4]. - Additional information regarding the reverse stock split is available in the Company's definitive proxy statement filed with the SEC [5]. Group 3: Company Overview - Streamline Health Solutions, Inc. provides solutions to healthcare organizations aimed at improving financial performance and addressing revenue leakage through integrated solutions and analytics [6].